Diabetes Management Devices Market Size, Share, Growth and Industry Analysis, By Type (Blood Glucose Monitoring Device and Insulin Delivery Systems), By Application (Hospitals, Clinics and Others), Regional Outlook, and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

DIABETES MANAGEMENT DEVICES MARKET OVERVIEW

The global Diabetes Management Devices Market is estimated to be valued at USD 56.62 Billion in 2026. The market is projected to reach USD 104.1 Billion by 2035, expanding at a CAGR of 7% from 2026 to 2035.

The Diabetes Management Devices Market is expanding as glucose monitoring, insulin delivery, and connected-care technologies become increasingly integrated into routine diabetes management. In 2025, approximately 589 million adults aged 20–79 were living with diabetes globally, while 252 million adults were estimated to be undiagnosed. More than 90% of diabetes cases are type 2 diabetes, creating a substantial need for blood glucose monitoring devices, continuous glucose monitoring systems, insulin pumps, smart insulin pens, and connected diabetes-management technologies. Continuous glucose monitoring is becoming increasingly important because devices can provide glucose information throughout the day and support treatment decisions, trend identification, and personalized management. Automated insulin delivery systems combine CGM data with insulin pumps and algorithmic control, creating an increasingly integrated device ecosystem.

The United States represents one of the most advanced markets for diabetes management devices, supported by a large diagnosed population, high adoption of continuous glucose monitoring, extensive insulin-pump use, and strong healthcare infrastructure. In 2023, approximately 40.1 million people in the United States had diagnosed or undiagnosed diabetes, representing 12.0% of the population. Approximately 29.1 million people had diagnosed diabetes, while 11.0 million adults with diabetes were estimated to remain undiagnosed. The U.S. also had approximately 115.2 million adults with prediabetes, creating a substantial addressable population for monitoring and preventive technologies. The increasing availability of connected CGM systems, automated insulin delivery, smart insulin pens, and remote patient-monitoring platforms is strengthening the U.S. Diabetes Management Devices Market.

KEY FINDINGS

LATEST TRENDS

Latest AID System Utilized to Continuously Track Blood Sugar Levels

The Diabetes Management Devices Market is increasingly shifting from standalone devices toward connected ecosystems that combine glucose sensing, insulin delivery, mobile applications, data analytics, and automated decision support. In 2025, diabetes technology guidance recognized real-time CGM and intermittently scanned CGM as important tools for people using insulin, while automated insulin delivery systems were emphasized for appropriate individuals with type 1 diabetes. CGM systems are also increasingly being considered for selected adults with type 2 diabetes who use glucose-lowering medications without insulin. This expansion increases the potential user base for wearable glucose-monitoring technology and connected diabetes-management platforms.

Consumer-accessible glucose technology is also broadening. Abbott introduced Lingo and Libre Rio in the United States as over-the-counter CGM systems, extending glucose-sensing technology beyond traditional prescription diabetes management. Meanwhile, data interoperability is becoming more important as CGM, smart pens, pumps, mobile applications, and digital health platforms generate millions of glucose and insulin data points. The Diabetes Management Devices Market is therefore increasingly centered on continuous monitoring, personalized insights, automated dosing, longer wear duration, connectivity, and simpler user experiences.

Download Free Sample to learn more about this report

DIABETES MANAGEMENT DEVICES MARKET SEGMENTATION

By Type

Based on type, the market is distributed into Blood Glucose Monitoring Device and Insulin Delivery Systems

• Blood Glucose Monitoring Device: Blood glucose monitoring devices represent approximately 56% of the Diabetes Management Devices Market based on device utilization and include traditional glucose meters, continuous glucose monitors, flash monitoring systems, sensors, readers, and connected glucose applications. The segment benefits from the basic requirement to monitor glucose levels in diabetes management. CGM adoption is particularly important because modern systems provide continuous or frequent readings and can generate alerts for high and low glucose levels. 

• Insulin Delivery Systems: Insulin delivery systems account for approximately 44% of the Diabetes Management Devices Market and include insulin pumps, automated insulin delivery systems, smart insulin pens, pen needles, cartridges, infusion sets, and related dosing technologies. Insulin pumps are increasingly integrated with CGM systems, enabling algorithms to adjust insulin delivery according to glucose trends. The development of automated insulin delivery is changing the competitive landscape because pump manufacturers increasingly compete on algorithm performance, sensor compatibility, ease of use, and connectivity. 

By Application

Based on application, the market is divided into Hospitals, Clinics and Others

• Hospitals: Hospitals account for approximately 31% of Diabetes Management Devices Market application activity because inpatient diabetes management requires accurate glucose monitoring, insulin administration, and continuous observation of patients with complex conditions. Hospital environments use bedside glucose meters, professional CGM systems, insulin pumps in selected circumstances, infusion technologies, and connected clinical data systems. Hospital demand is influenced by diabetes prevalence among admitted patients and by the need to manage glucose during surgery, critical illness, pregnancy, infection, and other conditions.

• Clinics: Clinics represent approximately 27% of application activity and include endocrinology centers, diabetes-management clinics, primary-care practices, specialty clinics, and outpatient facilities. Clinics frequently use CGM data to assess glucose trends, evaluate treatment effectiveness, identify hypoglycemia, and support medication adjustments. Professional CGM can provide several days of continuous information without requiring the patient to permanently own the device. The growing number of adults with type 2 diabetes is increasing the importance of outpatient diabetes-management technologies. In 2025, more than 90% of people with diabetes globally were estimated to have type 2 diabetes. Clinics therefore require devices that are easy to prescribe, apply, interpret, and integrate into routine care.

• Others: Other applications account for approximately 42% and include home care, pharmacies, diabetes education centers, long-term care, research institutions, sports and wellness programs, and remote patient-monitoring services. Home-based diabetes management represents a major portion of this segment because most diabetes care occurs outside hospitals and clinics. Consumer access to CGM is also broadening the market. Abbott introduced Lingo and Libre Rio in the United States as over-the-counter CGM systems, demonstrating the expansion of glucose biosensing beyond traditional prescription-based diabetes management. These systems create opportunities for earlier awareness of glucose patterns and broader engagement with metabolic health.

MARKET DYNAMICS

Driving Factor

Rising diabetes prevalence and increasing demand for continuous glucose monitoring

The rising number of people living with diabetes is the strongest structural driver for the Diabetes Management Devices Market. In 2025, approximately 589 million adults aged 20–79 were living with diabetes globally, representing approximately 11.1% of the adult population in that age group. Approximately 252 million adults were estimated to be unaware of their diabetes status, demonstrating the continuing need for diagnosis, monitoring, and long-term disease management. The number of adults with diabetes is projected to reach 853 million by 2050, creating sustained demand for glucose-monitoring and insulin-management technologies.

Restraining Factor

High device costs, reimbursement limitations, and technology complexity

Cost and reimbursement remain significant restraints for the Diabetes Management Devices Market because CGM sensors, insulin pumps, infusion sets, transmitters, smart pens, and related supplies often require recurring expenditure. A CGM system can involve sensor replacement every 7, 10, 14, or 15 days depending on the product, while insulin pumps require ongoing infusion-set and reservoir supplies. These recurring requirements can influence adherence, particularly when insurance coverage is incomplete or healthcare resources are limited.

Integration of CGM, insulin delivery, artificial intelligence, and digital health

Opportunity

Integration represents one of the largest opportunities because diabetes management generates continuous streams of glucose, insulin, activity, meal, and medication information. Modern CGM systems can communicate with insulin pumps, smartphones, smartwatches, and cloud-based platforms. Automated insulin delivery systems can use glucose information to adjust basal insulin, reducing the need for users to make every dosing decision manually. The integration of these technologies creates opportunities for manufacturers to develop comprehensive diabetes-management platforms rather than isolated devices.

Maintaining accuracy, interoperability, safety, and affordability simultaneously

Challenge

The Diabetes Management Devices Market faces the challenge of balancing accuracy, convenience, safety, connectivity, and affordability in a single product ecosystem. A CGM sensor must provide reliable glucose information while operating in a biological environment that can introduce signal variability. An insulin-delivery system must respond appropriately to sensor information without causing excessive insulin delivery. Automated systems therefore require carefully validated algorithms and multiple safety mechanisms. Interoperability is another major challenge because patients may use devices manufactured by different companies.

• Download Free Sample to learn more about this report

•  

DIABETES MANAGEMENT DEVICES MARKET REGIONAL INSIGHTS

• North America

North America accounts for approximately 39% of the Diabetes Management Devices Market and represents the leading regional market because of strong CGM adoption, established insulin-pump infrastructure, advanced healthcare systems, and extensive device reimbursement programs. The United States is the primary contributor, with approximately 40.1 million people living with diagnosed or undiagnosed diabetes in 2023. Approximately 29.1 million Americans had diagnosed diabetes, while 115.2 million adults had prediabetes.

Dexcom's G7 15 Day received FDA clearance in April 2025 and launched in the U.S. on December 1, 2025 for adults aged 18 years and older. The product offers up to 15.5 days of wear and an overall MARD of 8.0%. Medtronic also strengthened the U.S. market in April 2025 with FDA approval for Simplera Sync integration with MiniMed 780G. Abbott expanded its consumer CGM portfolio through Lingo and Libre Rio, increasing the potential reach of glucose biosensing beyond conventional prescription diabetes care. The combination of product innovation, reimbursement, healthcare infrastructure, and a large diabetic population maintains North America's leadership.

• Europe

Europe represents approximately 25% of the Diabetes Management Devices Market and benefits from developed healthcare systems, established diabetes-management programs, medical-device expertise, and high awareness of continuous monitoring. Germany, the United Kingdom, France, Italy, Spain, and the Nordic countries represent important markets for CGM and insulin-delivery technologies. European demand is supported by a substantial diabetes burden and increasing emphasis on early intervention and personalized care. Approximately 589 million adults worldwide were living with diabetes in 2025, while European healthcare systems increasingly focus on technologies that can improve glucose monitoring and reduce complications.

European markets also place strong emphasis on medical-device safety, clinical evidence, data privacy, and environmental considerations. The region's established pharmaceutical and medical-device industries provide opportunities for integrated diabetes platforms. Smart insulin pens, CGM sensors, connected glucose meters, and pump systems can support decentralized care. Germany and the United Kingdom remain particularly important markets because of their large healthcare systems and established diabetes-management infrastructure. European growth is also supported by increasing adoption of digital health and remote patient monitoring.

• Asia-Pacific

Asia-Pacific accounts for approximately 29% of the Diabetes Management Devices Market and represents a major long-term opportunity because of population size, diabetes prevalence, expanding healthcare infrastructure, and strong medical-device manufacturing capabilities. China, Japan, India, South Korea, and Australia represent key markets with different reimbursement systems and technology-adoption patterns. China and India are particularly important because of their large populations and substantial type 2 diabetes burden. Japan has a highly developed healthcare system and a strong medical-device industry, while South Korea is advancing connected healthcare and semiconductor-enabled medical technologies. 

Local manufacturers are developing glucose meters, CGM components, insulin-delivery devices, and digital monitoring platforms. The Asia-Pacific market is also benefiting from increasing smartphone penetration and digital connectivity. Mobile applications can provide glucose trend analysis, medication reminders, food logging, and remote communication with healthcare providers. As healthcare systems expand outside major urban centers, portable and connected diabetes-management devices can support decentralized care. The combination of 29% regional market activity and a large diabetes population creates significant opportunities for manufacturers offering cost-efficient and scalable technologies.

• Middle East & Africa

Middle East & Africa represents approximately 7% of the Diabetes Management Devices Market but offers significant unmet-need opportunities because diabetes prevalence is high in several countries and access to advanced monitoring technologies remains uneven. Saudi Arabia, the United Arab Emirates, South Africa, Egypt, and other major healthcare markets are increasing investments in chronic-disease management and digital healthcare. The region's diabetes burden is influenced by urbanization, obesity, sedentary lifestyles, aging, and dietary changes. More than 80% of adults with diabetes globally live in low- and middle-income countries, emphasizing the importance of accessible monitoring technologies. 

Private hospitals and specialist clinics are important early adopters of CGM and insulin-pump technologies. The United Arab Emirates and Saudi Arabia are also investing in digital-health infrastructure, creating opportunities for remote glucose monitoring and connected care. However, affordability, reimbursement, specialist availability, supply continuity, and patient education remain important barriers. Manufacturers can address these challenges through lower-cost sensors, longer-wear devices, durable hardware, local distribution, multilingual software, and remote education. The region's approximately 7% current market activity leaves significant room for technology penetration as healthcare infrastructure and chronic-disease programs expand.

KEY INDUSTRY PLAYERS

The Major Players of this Market are Involved in Intense Competition and Expansion into New Markets to Broaden their Shares

The diabetes management devices market has a low level of large and generic competitors. Several large companies, like Dexcom Medtronics, Abbott, and more generic businesses like Roche, Arkray, and Ascensia, respectively, dominate the markets for CGM and SMBG devices. A few multinational and domestic businesses, including Novo Nordisk, Eli Lilly and Company, Medtronic, and Becton Dickinson and Company, among others, are examined in the competitive landscape for insulin devices. As each competitor tries to create a brand-new device and sell it for a reasonable price, there is intense competition among the players. Players are also expanding into new markets, particularly emerging economies where demand is much higher than supply, in an effort to boost their market shares.

LIST OF DIABETES MANAGEMENT DEVICES MARKET COMPNIES

• Abbott Laboratories
• Dexcom
• Roche
• LifeScan
• Medtronic
• Terumo
• B. Braun Melsungen
• BD
• Ascensia (Bayer)
• Senseonics Holdings
• Johnson & Johnson
• Eli Lilly
• Novo Nordisk
• Sanofi
• Ypsomed Holding
• GlySens Incorporated
• Meiqi Medical Equipment
• San Meditech
• All Medicus

Top 2 Companies With Highest Market Share

• Abbott Laboratories: Abbott is estimated to hold approximately 29% of the global CGM segment, supported by the FreeStyle Libre portfolio, broad international distribution, multiple sensor configurations, and expansion into over-the-counter glucose biosensing.
• Dexcom: Dexcom is estimated to hold approximately 23% of the global CGM segment, supported by the G7 platform, connected glucose monitoring, automated insulin-delivery integrations, and the G7 15 Day system launched in the United States in December 2025.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment opportunities in the Diabetes Management Devices Market are increasingly concentrated in continuous glucose monitoring, automated insulin delivery, smart insulin pens, wearable biosensors, data analytics, and interoperable digital-health platforms. Approximately 56% of device utilization is associated with glucose monitoring technologies, making CGM and connected blood glucose monitoring major investment categories. Longer sensor wear represents an important product-development opportunity. Dexcom's G7 15 Day provides up to 15.5 days of wear, demonstrating the commercial value of reducing sensor replacement frequency. Manufacturers investing in longer-lasting sensors can compete through convenience, lower device-management burden, reduced waste, and improved continuity of monitoring.

Automated insulin delivery is another major investment area. Medtronic's MiniMed 780G integrates CGM information with automated insulin delivery, while other manufacturers are developing interoperable pump and sensor ecosystems. Approximately 44% of the market is associated with insulin delivery systems, creating opportunities for pumps, smart pens, infusion sets, dosing algorithms, and integrated platforms. Emerging investment opportunities also include artificial intelligence, predictive glucose analytics, remote patient monitoring, pediatric diabetes technologies, and non-insulin type 2 diabetes applications. The U.S. population alone included approximately 115.2 million adults with prediabetes in 2023, indicating a substantial population for future preventive and monitoring technologies.

NEW PRODUCT DEVELOPMENT

New product development in the Diabetes Management Devices Market is centered on longer sensor life, improved accuracy, smaller wearable designs, automated insulin delivery, and broader device connectivity. Dexcom's G7 15 Day, launched in the United States on December 1, 2025, provides up to 15.5 days of wear and reports an overall MARD of 8.0%. Longer wear reduces the frequency of sensor replacement compared with the company's earlier 10.5-day G7 system. Medtronic's Simplera Sync represents another important development. FDA approval in April 2025 expanded MiniMed 780G compatibility to another CGM sensor. The MiniMed 780G system can adjust insulin delivery based on sensor glucose values, while SmartGuard technology supports automated management. 

Abbott has also expanded beyond conventional prescription CGM through Lingo and Libre Rio, which were cleared as over-the-counter CGM systems in the United States. This development expands glucose-sensing technology toward consumers without traditional prescription access and supports broader metabolic-health applications. Connected dosing is another important product-development area. In November 2025, Dexcom received FDA clearance for Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults aged 18 years and older with type 2 diabetes using long-acting insulin. These developments demonstrate the market's shift from isolated monitoring toward integrated, data-driven, and increasingly automated diabetes management.

FIVE RECENT DEVELOPMENTS (2025-2026)

• April 2025: Medtronic received U.S. FDA approval for the Simplera Sync sensor for use with the MiniMed 780G system, expanding the CGM options available within its automated insulin delivery platform. The MiniMed 780G can automatically adjust insulin delivery based on sensor glucose readings, while the Simplera Sync sensor provides up to 6 days of use followed by a 24-hour grace period.

• April 2025: Dexcom received FDA clearance for the Dexcom G7 15 Day continuous glucose monitoring system, designed for adults aged 18 years and older with diabetes. The system provides up to 15.5 days of sensor wear, including a 12-hour grace period, and reports an overall MARD of 8.0%, strengthening the company's longer-duration CGM portfolio.

• November 2025: Dexcom received FDA clearance for Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults aged 18 years and older with type 2 diabetes using long-acting insulin. The system uses CGM readings and logged insulin doses to generate personalized basal-dose recommendations under healthcare-provider direction.

• December 2025: Dexcom launched the G7 15 Day system in the United States, making the longer-duration CGM available initially through durable medical equipment providers. The system provides up to 15.5 days of wear and includes an overall MARD of 8.0%, while compatibility with connected applications and remote data sharing supports broader digital diabetes management.

• February 2026: Medtronic expanded its MiniMed 780G access and sensor options in the United States, including availability of the system for insulin-requiring adults with type 2 diabetes and integration with additional sensor technologies. The development expands automated insulin-delivery access across diabetes populations and strengthens the company's full-stack approach combining CGM, insulin pumps, algorithms, and connected diabetes management.

REPORT COVERAGE

The Diabetes Management Devices Market report covers blood glucose monitoring devices and insulin delivery systems across hospitals, clinics, and other healthcare environments. The study analyzes 2 primary device categories, including glucose monitoring and insulin delivery, and 3 application groups consisting of hospitals, clinics, and other settings. The report evaluates continuous glucose monitoring, blood glucose meters, sensors, readers, insulin pumps, infusion sets, smart pens, connected dosing systems, and automated insulin delivery technologies. The regional assessment covers North America, Europe, Asia-Pacific, and Middle East & Africa, with emphasis on diabetes prevalence, healthcare infrastructure, reimbursement, device adoption, regulatory environments, manufacturing capabilities, and technology penetration. 

The report also examines sensor wear duration, accuracy, connectivity, interoperability, cybersecurity, patient usability, and data integration. Recent market developments include 5 major product and technology developments during 2025 and 2026, covering CGM expansion, longer-duration sensors, automated insulin delivery, CGM-integrated dosing optimization, and expanded access for insulin-requiring type 2 diabetes. The report evaluates market drivers, restraints, opportunities, challenges, segmentation, regional performance, competitive positioning, investment opportunities, and new product development without using revenue or CAGR metrics.